Geron (GERN) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Geron (GERN) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 52.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.03% |
| Mar 31, 2026 | -29.15% |
| Dec 31, 2025 | 49.68% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | 38.50% |
| Mar 31, 2025 | 49.32% |
| Dec 31, 2024 | 47.44% |
| Sep 30, 2024 | -25.56% |
| Jun 30, 2024 | -69.01% |
| Mar 31, 2024 | 76.95% |
| Dec 31, 2023 | 46.42% |
| Sep 30, 2023 | -47.15% |
| Jun 30, 2023 | -184.02% |
| Mar 31, 2023 | 103.39% |
| Dec 31, 2022 | 15.62% |
| Sep 30, 2022 | -90.56% |
| Jun 30, 2022 | -64.13% |
| Mar 31, 2022 | 2.05% |
| Dec 31, 2021 | 67.62% |
| Sep 30, 2021 | -64.05% |